Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

Hulu Nicholas Hunt/Getty; Kristina Bumphrey/Getty Jim Gaffigan in 2019 and in 2024. Comedian Jim Gaffigan is the first to ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

Utah Trim Clinic has what you need to get rid of stubborn body fat, lose weight, tone your body or just keep it as it is, even during the holidays.

BELLEVUE, Wash., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Truveta announced today that Truveta Data, the most complete, timely, and clean electronic health record (EHR) data, now includes more than 120 ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Researchers at the University of Copenhagen have identified a promising new drug target for weight loss which could revolutionise treatment for millions of people with obesity and type 2 diabetes. The ...